Liver Biopsy Insurance Denied? How to Appeal

A liver biopsy provides diagnostic information that no other currently available test can fully replicate. By examining liver tissue under a microscope, pathologists can determine the precise degree of inflammation, the stage of fibrosis (scarring), and whether cirrhosis has developed — information that directly governs treatment decisions for conditions including hepatitis B (ICD-10: B18.1), hepatitis C (B18.2), nonalcoholic fatty liver disease and NASH (K75.81), autoimmune hepatitis (K75.4), and primary biliary cholangitis (K74.3). When insurance denies a liver biopsy, it can block your physician's ability to accurately stage your disease and select the right treatment. These denials are frequently reversible with the right documentation.

Why Insurers Deny Liver Biopsies

Non-invasive alternatives claimed to be sufficient. The most significant source of liver biopsy denials in recent years has been the rise of non-invasive fibrosis assessment tools: FibroScan (transient elastography), serum fibrosis panels including FIB-4 score and APRI, and MR elastography. Insurers may deny biopsy coverage on the grounds that these alternatives can adequately assess fibrosis stage. However, the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) guidelines specifically identify clinical situations where liver biopsy remains the gold standard and non-invasive tests are inadequate — including discordant non-invasive test results, suspected mixed or overlapping liver disease, evaluation before initiating immunosuppressive therapy for autoimmune hepatitis, and pre-transplant assessment.

Medical necessity criteria not clearly met. Insurers apply internal Clinical Policy Bulletins specifying when liver biopsy is covered. If your physician's documentation does not map directly to the insurer's listed covered indications with supporting ICD-10 codes and clinical findings, the claim is denied for lack of medical necessity even when the procedure is clinically appropriate.

Procedure classified as diagnostic rather than therapeutic. Some insurers apply coverage criteria differentially to diagnostic biopsies versus therapeutic procedures, resulting in denial or reduced coverage for diagnostic liver biopsies even when the diagnosis drives imminent treatment decisions.

NAFLD/NASH staging dispute. For nonalcoholic fatty liver disease and steatohepatitis, insurers may question whether distinguishing simple steatosis (K76.0) from NASH with fibrosis (K75.81) is clinically necessary. The AASLD and American Gastroenterological Association (AGA) guidelines support biopsy when the distinction will change clinical management — specifically when antifibrotic therapy or clinical trial enrollment is being considered.

Post-transplant or pre-transplant biopsy denied. Liver biopsy in transplant evaluation or post-transplant rejection assessment is clinically essential and supported by transplant society guidelines, yet insurers occasionally deny these claims on broad medical necessity grounds.

How to Appeal a Liver Biopsy Denial

Step 1: Request the Full Denial Documentation and Insurer's Coverage Criteria

Ask your insurer for the complete denial letter and the Clinical Policy Bulletin (CPB) applied to liver biopsy. Identify which criteria your claim allegedly did not meet, then cross-reference your existing documentation against each criterion before building your appeal.

Step 2: Obtain Your Gastroenterologist or Hepatologist's Letter

Your specialist's letter is the cornerstone of the appeal. It should state your specific diagnosis with ICD-10 codes; explain precisely what clinical question the biopsy is intended to answer and how the answer will change your treatment; document the results of any non-invasive fibrosis assessments already performed (FibroScan, FIB-4, APRI) and why they are insufficient or discordant in your case; reference AASLD practice guidelines and AGA clinical guidelines supporting biopsy for your specific indication; and state explicitly that liver biopsy is medically necessary for this patient.

Step 3: Compile AASLD and Society Guideline Support

Gather the AASLD Practice Guidance on the Evaluation and Management of Nonalcoholic Fatty Liver Disease, AASLD guidelines for hepatitis B and hepatitis C management, AGA clinical practice guidelines relevant to your diagnosis, and any relevant peer-reviewed literature from journals such as Hepatology or Journal of Hepatology that specifically addresses your indication. These documents carry significant weight in medical necessity appeals.

Step 4: Document Why Non-Invasive Testing Is Insufficient in Your Case

Address the specific non-invasive alternatives directly. If FibroScan was performed and showed indeterminate results (LSM between 7 and 12 kPa in a NAFLD patient with obesity), document this. If the FIB-4 score falls in the indeterminate range (1.3–2.67), document this. If multiple non-invasive tests produced discordant results, document the discordance specifically. AASLD guidelines specifically support biopsy in these indeterminate scenarios.

Step 5: File Your Internal Appeal

Submit a written appeal within the deadline in your denial letter — typically 180 days for post-service claims under ACA § 2719 (42 U.S.C. § 300gg-19) or as specified in your ERISA plan under 29 U.S.C. § 1133. Request review by a board-certified gastroenterologist or hepatologist rather than a generalist reviewer. State explicitly which AASLD or AGA guideline criterion supports the procedure for your specific indication.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review if Internal Appeal Fails

After exhausting internal appeals, request independent external review by a clinical reviewer not affiliated with your insurer. The IRO decision is binding on the insurer. Request that the reviewing clinician have gastroenterology or hepatology expertise.

What to Include in Your Appeal

• Denial letter with specific reasons and the insurer's CPB for liver biopsy
• Gastroenterologist or hepatologist letter with ICD-10 codes, clinical indication, and explicit AASLD/AGA guideline citations
• Results of all non-invasive fibrosis assessments performed (FibroScan LSM values, FIB-4 score, APRI) with documentation of indeterminate or discordant findings
• Prior treatment history and liver enzyme trends (ALT, AST, GGT)
• AASLD practice guidance excerpts specifically supporting biopsy for your indication

Fight Back With ClaimBack

Liver biopsy denials frequently turn on whether the insurer's clinical criteria adequately account for AASLD guideline-supported indications — and the published evidence strongly supports biopsy in a wide range of liver disease staging scenarios where non-invasive testing is insufficient. ClaimBack generates a professional appeal letter in 3 minutes tailored to your liver disease diagnosis and the specific grounds for your denial.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal